ClinicalTrials.gg
RecruitingNCT05586334PrediMAPUpdated Nov 20, 2025

Development and Clinical Evaluation of an Innovative Medical Device to Predict Preterm Birth (PrediMAP)

An interventional study of Collection of vaginal secretions and Collection of the placenta and the membranes in Preterm Labor, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Primary conditionPremature BirthRegistry: Obstetric Labor, PrematureReclassifiedWhy we changed it
Registry
Obstetric Labor, Premature — the first condition term the registry derived for this study.
ClinicalTrials.gg
Premature Birth
Why
  1. The study's title name Premature Birth, a narrower term within Obstetric Labor, Premature.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,600
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 2 of them phase 3. Premature Birth · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
Largest of 20
3,600 · median 133
Started
2023
with 1 other
No phase
12 of 26
3 open now
Registered
21st of 26
by date

Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2023, is one of 12 with no phase, and was the 21st registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

6 of the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The purpose of this study is to clinically validate the predictive performance (sensitivity and specificity) of the PrediMAP in-vitro diagnostic medical device to predict delivery within 7 days in the target population of women consulting obstetric emergencies for preterm labor (PTL).

Read the detailed description

Preterm delivery (birth before 37 weeks of gestation) accounts for 12% of worldwide births each year: 15 million children. It is the leading cause of infant mortality. In France, it accounts for 60,000 births per year, 10,000 of them very preterm (before 32 weeks) and at very high risk of neonatal complications and childhood sequelae Given the high risks of death and of neurodevelopmental disabilities and learning disorders among survivors, preterm birth (PTB) is a major public health problem .

Over the past 30 years, measures to prevent preterm deliveries have not proved effective, and the incidence of PTB is rising or at best stable in most developed countries, including France. Important advances have nonetheless improved the management of pregnancies at risk of PTB and of preterm children.

From 100,000 to 150,000 women a year come to maternity unit EDs for symptoms suggesting PTL. Although fewer than half will be admitted to the hospital, our team has shown that PTL is the leading reason for hospitalization among pregnant women (45,000 admissions/year) in France [4]. In the USA, PTL is also the main cause of hospitalization during pregnancy, with costs estimated at $820 million annually . This hospitalization benefits only those women who finally do give birth preterm.

The PrediMAP project's ambition is to use new markers involved in the mechanism of PTL in clinical practice - biomarkers that are the fruit of more than 10 years of basic research at the Institut Cochin. The objective is to combine their measurement with clinical and ultrasound data to construct an algorithm to predict PTB within 7 days after the test, one that medical teams can use in obstetric EDs.

The final objective is to obtain a personalized prediction of delivery within 7 days via an algorithm integrated in the IVD-MD that includes clinical and ultrasound data with these biomarker measurements.

This study is conducted in 3 phases (3 cohorts).

  • Objectives of Cohort 1 (Development) :

    1. Collect vaginal samples for development of the device
    2. Collect clinical and ultrasound data for the predictive algorithm
    3. Collect placenta and membrane samples to identify additional biomarkers
  • Objective of Cohort 2 (Technical validation ): Validate technically the ergonomics and reliability of the bedside device
  • Objective of Cohort 3 (Clinical performance) : Validate the clinical performance of the PrediMAP solution in the target population
03

Conditions studied

  • Preterm Labor

Browse trials for

Keywords

  • obstetrics
  • medical device
  • preterm labor
  • preterm birth
  • prediction
04

In context

Premature Birth Reclassified

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

This study's planned enrollment of 3,600 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Premature Birth, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obstetric Labor, Premature. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant with live fetus(es)
  • Emergency room visit between 22 and 34 days of pregnancy + 6 days
  • For a suspicion of PTL defined by :

    • Uterine contractions (UC) objectified during the consultation (questioning, clinical examination, external tocography),
    • And/or clinical or ultrasound changes of the uterine cervix;
  • OR for any other reason but with EC and/or clinical or ultrasound changes of the cervix on clinical examination
  • Social security coverage or AME: patients receiving AME are at higher risk of PAD and preterm delivery.
  • Signature of consent

Exclusion criteria

Exclusion Criteria

  • Age \< 18 years;
  • Premature rupture of membranes
  • Patient in labor with imminent delivery.
  • Total absence of social care
  • Minor or protected adult (guardianship or curatorship)
  • Persons who do not speak French and not accompanied by a French-speaking third party
  • Multiple pregnancy >= 3
06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
3,600 participants (estimated)

Interventions

  • BiologicalCollection of vaginal secretions

    In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.

  • BiologicalCollection of the placenta and the membranes

    In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery

  • OtherAdministration of EPDS questionnaire

    In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.

07

What researchers measure

Primary outcomes

  1. Delivery occurence 7 days after inclusion

    Time frame: Cohort 1 : assessed 15-21 days after inclusion of each patient. Cohort 3: assessed after end of follow-up (5.5 months).

Secondary outcomes

  1. delivery occurrence 14 days after consultation

    Time frame: assessed after end of follow-up (5.5 months)

  2. delivery <32 weeks of gestation, <34 weeks and <37 weeks

    Gestational age at delivery, in 4 categories.

    Time frame: assessed after end of follow-up (5.5 months)

  3. neonatal mortality;

    Time frame: assessed after end of follow-up (5.5 months)

  4. severe neonatal morbidity

    Defined by one or more of the following : * Bronchopumonary dyplasia * Necrotizing enterocolitis stage 2 or 3 * Intraventricular haemorrhage stage 3-4 * Periventricular leukomalacia * Retinopathy of prematurity stage \>3

    Time frame: assessed after end of follow-up (5.5 months)

  5. EPDS score at inclusion and after delivery

    Time frame: assessed after end of follow-up (5.5 months)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 48 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 48 months is above that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Oct 19, 2022
StartActual
Jun 8, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05586334
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Oct 19, 2022
Start date
Jun 8, 2023
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

Jeanne SIBIUDE, MD, PhD
Contact
jeanne.sibiude@aphp.fr
+33 1 47 60 66 11
Karima MESBAHI IHADJADENE, Project Manager
Contact
karima.mesbahi@aphp.fr
33 1 58 41 12 11
Jeanne SIBIUDE, MD, PhD
principal investigator · APHP
François GOFFINET, Pr
study chair · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion